As part of the agreement, Zurich headquartered DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon's brand.
"This collaboration will enable us to address the growing patient needs for affordable access to high-quality generics for chronic diseases and expand our commercial footprint in this region," said Siddharth Mittal, CEO & Managing Director, Biocon, with annual revenues of 837.5 million U.S. dollars. "Together with Biocon Pharma, we can help a lot of patients in Asia who require advanced therapies for chronic diseases."
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Indian company launches drug to treat mild, moderate Covid-19 patients; another gunfight breaks out in KashmirMUMBAI (Xinhua): Glenmark Pharmaceuticals has become the first Indian company to launch anti-viral drug Favipiravir for the treatment of mild to moderate Covid-19 patients in the domestic market following the manufacturing approval from the drug regulator, a company statement said.
続きを読む »